Last reviewed · How we verify

NCT06063213: TGI

Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation

Active, enrolled Last updated 4 March 2026
What this trial tests

trial in Transplant Complication in 40 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
15 December 2023
Primary endpoint
15 October 2026
15 October 2026

Quick facts

Lead sponsorUniversity of Florida
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment40
Start date15 December 2023
Primary completion15 October 2026
Estimated completion15 October 2026
Sites1 location across United States

Conditions studied

Sponsor

University of Florida

Who can join

Adults 18 to 90, any sex, with Transplant Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To develop a prospective quantitative liver allograft monitoring protocol and retrospectively validate the use of Phenotypic personalized medicine (PPM) in immunosuppression dosing in liver transplant recipients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Transplant Complication

Currently open trials in the same condition.

Other University of Florida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06063213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing